Last updated on April 2019

Alternatives for Reducing Tics in TS: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents.


Brief description of study

This is a study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717) tablets for the reduction of motor and phonic tics associated with TS in children and adolescents 6 through 16 years of age.

Clinical Study Identifier: NCT03452943

Find a site near you

Start Over

Teva Investigational Site 046-0114

Saint Petersburg, FL United States
  Connect »

Teva Investigational Site 046-0110

Saint Charles, MO United States
  Connect »

Teva Investigational Site 046-0106

Oklahoma City, OK United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.